Just to clarify: Rohan said they've filed for IP protection for two CNS candidates. He said they have a focus on autophagy production (a pathway in neurogenerative diseases) and neuroinflammation (see below the patents for autophagy and inflammation). Another program PYC were working on targeting progranulin was halted due to Roche gaining the intellectual property rights. Sorrow for any confusion.
PYC, page-43
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.005(4.35%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.8¢ | 11.0¢ | $297.5K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1372418 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 390472 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |